Vaccinex Presented Previously Disclosed Data from Ongoing Phase 1/2 Trial of VX15/2503

Vaccinex (Nasdaq:VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders, today announces vice president of preclinical research, Elizabeth Evans, Ph.D., provided a podium presentation at the Cambridge Healthtech Institute’s 18^th Annual PepTalk on the company’s anti-SEMA4D research and data from its Phase 2 trial in Huntington’s Disease.

As quoted in the press release:

“We are honored to again be invited to share our findings with the scientific community on the antibody blockade of the SEMA4D molecule, and its potential for treating neurodegenerative disease. We continue to be optimistic regarding the potential of our molecule, pepinemab, and look forward to providing further clinical updates,” said Maurice Zauderer, Ph.D., CEO of Vaccinex.

Dr. Evans’s presentation, “An Emerging Role for Glial Cells and Guidance Molecules in Neurodegeneration,” outlines the pathogenic role that the SEMA4D protein plays in neurodegeneration and the company’s experience with its monoclonal antibody, VX15 (pepinemab), in blocking the molecule. The CHI PepTalk was held January 14-15 at the Hilton San Diego Bayfront in San Diego, Calif.

Click here to read the full press release.